Medicus Pharma proposes $135 million SPAC listing for SkinJect
Medicus Pharma said on November 4 that SkinJect, its wholly owned subsidiary, signed a preliminary non-binding agreement with an unnamed SPAC that values SkinJect at $135 million before financing. The proposed transaction would place SkinJect in a separate listed company, with Medicus seeking majority economic and voting control, while new equity would fund the SKNJCT-005 Gorlin syndrome study and potential New Drug Application work. Medicus is targeting completion in the first half of 2027, subject to definitive agreements, financing, approvals and other closing requirements.
Why it matters
The proposed structure could give SkinJect its own public-market financing vehicle while allowing Medicus to retain majority control and exposure to the asset. Completion is not assured because the arrangement remains non-binding and depends on financing, due diligence, regulatory and shareholder approvals, and other conditions.
Key facts
- 1The proposed business combination assigns SkinJect a $135 million valuation before money. finance.yahoo.com
- 2Medicus expects the transaction to close in the first half of 2027. finance.yahoo.com
- 3The FDA has authorized the start of SKNJCT-005, a planned registrational Phase 2b study for SkinJect. finance.yahoo.com
- 4The proposed transaction still requires definitive documentation, financing, a minimum-cash condition, board and shareholder approvals, SEC filings, registration requirements and stock-exchange approval. stocktitan.net
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.